



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS GRANTED 1.2 MILLION EURO IN RESEARCH TAX CREDIT

Paris, June 26, 2013 – NEOVACS (Alternext Paris: ALNEV), a leader in therapeutic vaccines for the treatment of autoimmune diseases announced today that it has received 1.2 million Euros in research tax credit for R&D expenses incurred in 2012.

“Investment is key for innovative companies like NEOVACS. R&D makes up for 75% of our expenses. The funds that we receive today strengthen our financial position, and show real public support for research and innovation in auto-immune diseases.” commented Guy Charles Fanneau de La Horie, CEO of NEOVACS.

The funds received today will be dedicated to future clinical development of the company.

About NEOVACS

NEOVACS is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. The company’s proprietary technology covered by five patent families that run until at least 2023 has generated to date 2 product candidates in 3 severe diseases: TNF-Kinoid for Rheumatoid Arthritis and Crohn’s Disease and IFN α -Kinoid for Lupus. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts

Presse – ALIZE RP

Caroline Carmagnol
+33 (0)1 42 68 86 43
caroline@alizerp.com

NEOVACS

Nathalie Trépo
+33 0 1 53 10 93 00
ntrepo@neovacs.com

Investors / NewCap

Valentine Brouchet
+ 33 (0) 1 44 71 94 93
neovacs@newcap.fr